Current status of sinonasal cancer survivorship care
Head & Neck · 2023
DOI: 10.1002/hed.27457 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Head & Neck, 2023. Verfasst von Albert Y Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Paranasal Sinus Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Sinonasal cancer is a heterogeneous orphan disease of diverse histologies, each with distinct clinical, oncologic, and toxicity profiles. Because of the comparative rarity of these cancers, sinonasal cancers are treated as a grouped diagnosis despite their clinical and biological heterogeneity. Multimodality treatment with a combination of surgery, chemotherapy, and/or radiotherapy is the standard‐of‐care for advanced‐stage patients but there are few surveillance or follow‐up practice guidelines or formalized survivorship care pathways. A scoping literature review was conducted via PubMed, EMBASE, and Google Scholar. A total of 112 studies were included, which were grouped along the following topics: surveillance, second primary tumors, quality of life, and symptom burden. Sinonasal cancer tends to exhibit a higher rate of local failure and occur in a delayed fashion compared to mucosal malignancies of the head and neck. Moreover, the site of failure and time‐varying risk of recurrence is histology‐specific. Following multimodality treatment of the skull base, patients may experience endocrine, visual, auditory, sinonasal, olfactory, and neurocognitive deficits, as well as psychosocial impairments that impact multiple physical and neuropsychological domains, resulting in diminished quality of life. Sinonasal cancer patients would benefit from tailored, histology‐specific survivorship programs to address the recurrence, second primary, and functional impairments resulting from disease and treatment toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
- Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Albert Y Han, Shirley Y Su
Zitieren
APA
Han, A. Y., Nader, M. E., Lam, K., & Su, S. Y. (2023). Current status of sinonasal cancer survivorship care. Head & Neck. https://doi.org/10.1002/hed.27457
Vancouver
Han AY, Nader ME, Lam K, Su SY. Current status of sinonasal cancer survivorship care. Head & Neck. 2023. doi:10.1002/hed.27457
BibTeX
@article{Han2023,
author = {Han, Albert Y and Nader, Marc-Elie and Lam, Keng and Su, Shirley Y},
title = {Current status of sinonasal cancer survivorship care},
journal = {Head & Neck},
year = {2023},
doi = {10.1002/hed.27457}
}
EUVIMED